Macitentan in daily clinical practice: A single centre, 1-year experience

• Published in: Pulmonology Vol. 24; no. 3; pp. 170 - 173
• Main Authors: Cadenas-Menéndez, S, Álvarez-Vega, P, Martín-Moreiras, J, Barreiro-Pérez, M, Gómez-Sánchez, M.Á, Sánchez-Fernández, P.L
• Format: Journal Article
• Language: English
• Published: Spain Taylor & Francis 01-05-2018
• Subjects: Internal Medicine; Pulmonary/Respiratory; Macitentan; Prostaglandins; Pulmonary arterial hypertension; Endothelin-receptor antagonist; Clinical practice; Phosphodiesterase 5 inhibitors
• ISSN: 2173-5115; 2531-0437; 2173-5115; 2531-0437
• DOI: 10.1016/j.rppnen.2017.10.001

AbstractThe effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events. Our aim was to describe a single centre's experience of the utilization of macitentan in patients with PAH in clinical practice settings. Thirteen patients with different aetiologies and previous PAH treatments were studied. After 12 months of macitentan treatment, 11 patients improved their functional class (FC), all patients improved their 6-minute walk distance (6MWD) test, and 10 patients lowered their NT-proBNP plasma levels. Additionally, cardiac imaging parameters were also improved. No cases resulted in hospitalization, septostomy, transplant or death.